David Stroncek, MD is Chief of the Cell Processing Section (CPS) of the Department of Transfusion Medicine (DTM), Clinical Center, NIH. CPS manufactures and develops a wide variety of cellular and gene therapy products to treat Clinical Center patients. These include hematopoietic progenitors and donor lymphocytes to support hematopoietic stem cell transplantation protocols and a number of IND products for phase I/II clinical trials including dendritic cells, Natural Killer cells, genetically engineered T cells and CD34+ cells, bone marrow stromal and culture expanded T cells. Dr. Stroncek research is focused on investigating new measures of cell and gene therapy quality and potency, particularly dendritic cells and NK cells.
He has a Bachelorís of Science degree in Chemical Engineering from the University of Minnesota. He completed medical school Medical, an Internal Medicine Internship and Residency and a Hematology and Oncology Fellowship at the University of Minnesota Medical School.
For information please contact email@example.com